Therapeutic effect of yttrium oxide nanoparticles for the treatment of fulminant hepatic failure.

To explore the potential therapeutic effect of yttrium oxide nanoparticles (YO NPs) on fulminant hepatic failure. RAW264.7 cells and a lipopolysaccharide/D-galactosamine-induced hepatic failure murine model were used to assess the effects of YO NPs. YO NPs exhibited anti-inflammatory activity by scavenging cellular reactive oxygen species and dampening reactive oxygen species-mediated NF-κB activation . A single intraperitoneal administration of YO NPs (30 mg/kg) enhanced hepatic antioxidant status and reduced oxidative stress and inflammatory response in lipopolysaccharide/galactosamine-induced mice. YO NPs also attenuated hepatic NF-κB activation, cell apoptosis and liver injury. YO NP administration could be used as a novel therapeutic strategy for treating fulminant hepatic failure and oxidative stress-related diseases.